Revolution Medicines (RVMD) Stock Dips as Exec Sells $3.5M — But Analysts Aren’t Flinching

TLDR

• Chief Global Commercialization Officer Anthony Mancini sold 26,552 shares worth ~$3.5M on March 25, under a pre-set 10b5-1 plan
• RVMD opened at $94.29, down 1.3%, with a 52-week range of $29.17–$124.49
• Truist Financial upgraded RVMD to “strong-buy” on March 26, joining Jefferies, Evercore, UBS, and Wedbush with bullish ratings
• Insiders sold ~149,592 shares (~$15M) in the past 90 days, while institutional ownership sits at 94.34%
• Q4 2025 EPS came in at -$1.86, missing the -$1.56 consensus, driven by higher R&D and SG&A costs

Revolution Medicines (RVMD) stock opened at $94.29 on Wednesday, March 26, down 1.3% on the day.

Revolution Medicines, Inc., RVMD

Anthony Mancini, the company’s Chief Global Commercialization Officer, sold 26,552 shares on March 25 for approximately $3.5 million. The sales were made at prices ranging from $93.22 to $97.21.

The transactions were executed under a 10b5-1 trading plan that Mancini adopted on December 24, 2025. That’s a pre-scheduled plan, meaning the sales were planned well in advance and aren’t necessarily a signal of his outlook on the stock.

Mancini also exercised options to acquire 37,450 shares at $33.62 per share, totaling about $1.26 million. After all transactions, he directly holds 54,400 shares and 54,400 restricted stock units.

He isn’t the only insider who has been selling. Fellow insider Mark A. Goldsmith sold 12,871 shares on March 17 at an average of $99.48, for just over $1.28 million. CFO Jack Anders also sold 2,753 shares that same day at the same price, for roughly $274,000.

In total, insiders have sold about 149,592 shares worth $15 million over the past 90 days. Insider ownership stands at 8.20%.

Truist Upgrades to Strong-Buy

Despite the insider selling, analyst sentiment is largely positive. Truist Financial upgraded RVMD to “strong-buy” on March 26.

Evercore made the same call back on February 25. Jefferies initiated with a “buy” on March 16. UBS also started coverage with a “buy” on February 27.

The lone bear is Weiss Ratings, which holds a “sell (d-)” rating. MarketBeat’s consensus sits at “Buy” with an average price target of $78.94 — well below the current trading price.

Individual targets are more generous. Piper Sandler raised its target to $120 (Overweight), Wells Fargo went to $144, and Needham sits at $145 with a Buy rating.

Institutions Loading Up While Earnings Miss

On the institutional side, the money has been flowing in. Norges Bank added a new position worth ~$195.6 million in Q4. Avoro Capital came in with ~$172.8 million. UBS boosted its stake by 183.6% to 3,087,937 shares, valued at nearly $246 million. Polar Capital ramped up by 321.2%, now holding over 2 million shares.

Institutional investors collectively own 94.34% of RVMD.

The bullish positioning comes despite a Q4 2025 earnings miss. The company reported a loss of $1.86 per share, against a consensus estimate of -$1.56, a gap of $0.30. The miss was attributed to higher-than-expected R&D costs and SG&A expenses.

Revenue was not the issue — the company ended the quarter with $2.03 billion in cash and investments, partly thanks to a deal with Royalty Pharma. Analysts project a full-year EPS of -$3.49 for fiscal 2026.

RVMD has a 50-day moving average of $101.53 and a 200-day moving average of $78.24. The stock has a market cap of $18.69 billion.

Over the past year, RVMD has surged 145%. Over the past six months, it’s up 112%.

The post Revolution Medicines (RVMD) Stock Dips as Exec Sells $3.5M — But Analysts Aren’t Flinching appeared first on CoinCentral.